Gilead (GILD) Harvoni/Sovaldi Label Changes Are Not Meaningful, Baird Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Gilead (GILD) Weakness Following HCV Warning Seen as Potential Buying Opportunity
March 23, 2015 6:41 AM EDTWells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $123-$127. Analyst Brian Abrahams commented on a... More
iShares Nasdaq Biotechnology (IBB) Poised to Open Up Over 2%
March 20, 2015 8:11 AM EDTiShares Nasdaq Biotechnology (NASDAQ: IBB) is poised to open higher by over 2%. Top holdings in the ETF are Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN).
